Member Info for beinthelead

Touk - that was your opinion on the investment case. Thanks for replying.

Please, again, provide your measure of success.

Thorn - How many patients required to expedite a Phase 2 trial of this nature? And/or gain accelerated approval?

Thanks.

Derek. Question.

What does success look like for you here? Concise please.

Still amazes me he’s got so many following his lead. TW has had more success here. Imagine that; TW and Ophidian the same person, just playing with us?! Argh!

But seriously, who STILL listens to them?

Just collecting shares before news drops this week. Ophidian said.

Hahahahaha got to laugh at eggy and his obsessions. Bishop was obsessive. Few others too. All got to be him. Can’t be that many lunatics hate little old Avacta.

It’s literally hilarious.

It’s a fair view. But it’s been like this for well over 12 mo this. Ripley did the right thing, absolutely. There’s nothing to add here.

AS is getting on with it now. Binning P1b was the rocket on that front. We’d be here til the patent ran out if was up to him.

SoleBoy - promoting this week as a news week. You may be correct, but it conspicuously aligns with Ophidians roll out. As do most of the TG campaigns.

I believe you are part of the TG, but cannot prove it.

SoleBoy clearly part of the TG group, promoting the latest ramp.

Of course the KoLs can reference ongoing clinical trials. Of course they can make ref to AVA6000. Of course Twelves made direct ref to AVA6000 as ‘chalk and cheese’.

Load of rubbish, sandwiched between a Big Mac.

This new angle is hot on the heels of the license deal stuffs from a few weeks back. Yet another cycle.

Well said. Who’d have thought data would be a SP driving event?!

It won’t make any difference timster. There’s enough points on the graph.

They are likely to include the C7 narrative in the release.

We can’t wait another 2 months for C7 data to be QC’d and added.

The no treatment related cardio tox is not the headline here. That’s been known for a while. And a lot of other therapies can say the same. It’s not that big of a deal.

The lack of haematological AE is a big thing. This should be promoted. By the main story, at this stage, is the presented efficacy. This was the major change we saw in the summer, post AGM.

They’ll release an RNS. Nothing journal related. Consillium will be turned on also.

It’ll be on an Avacta template. Don’t over complicate a simple issue.

Thorn - the trial continues to progress the AVA6000 product. They could wrap the entire thing now and sell the tech, as it works.

That clearer?? I have zero interest in products. The tech holds the value. Hence my calmness in the face of the mad onslaught of negativity.

They did that a long time ago, especially Derek. It’s beyond engagement.

And the delivery mechanism is all that needs to be proven. Nothing to see here.

How far are we away from seeing value extracted from Affyxcell?

The role is either required, or it isn’t.

I’ll email AS.

Thanks. But I’ll reserve judgement - I can understand the “very personal details” being withheld in notes, but there’s nothing sensitive about stating it was turned down. After all, you’ve just wrote it on a BB, that all the TG members will read?

“ The company had offered the position to one particular person, but due to personal and private circumstances, that individual was unable to join. The position is to be filled in due course.”

Which RNS please? Or TG notes?